Announcements Trials
Browse Landscape

Phase

Phase 1/2 12Phase 2 3Phase NA 2Phase 3 2Phase 1 2Phase 4 1

Status

Active not recruiting 2

Sponsor Class

OTHER 117NIH 6INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Prostate Adenocarcinoma 1Adenocarcinoma 1

Interventions

pembrolizumab 301Paclitaxel 206Carboplatin 199Gemcitabine 173Cisplatin 138Docetaxel 137Cyclophosphamide 135Nivolumab 129Bevacizumab 118Injections 111fludarabine 95atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 70Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Radiosurgery × Clear all
NCT04644770 2026-05-08

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Active not recruiting
144 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04943536 2026-02-27

BiolenRT

Alessa Therapeutics Inc.

Phase 1 Active not recruiting
20 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡